R Moroose

971 total citations
17 papers, 367 citations indexed

About

R Moroose is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, R Moroose has authored 17 papers receiving a total of 367 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in R Moroose's work include Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (6 papers). R Moroose is often cited by papers focused on Advanced Breast Cancer Therapies (7 papers), Cancer Treatment and Pharmacology (7 papers) and HER2/EGFR in Cancer Research (6 papers). R Moroose collaborates with scholars based in United States, Spain and Ireland. R Moroose's co-authors include Leon W. Hoyer, Bruce Furie, BC Furie, Jeffrey N. Weitzel, IA Mayer, Joyce O’Shaughnessy, Aditya Bardia, Jennifer R. Diamond, Linda T. Vahdat and Kevin Kalinsky and has published in prestigious journals such as Blood, Cancer Research and British Journal of Cancer.

In The Last Decade

R Moroose

14 papers receiving 357 citations

Peers

R Moroose

ONCOL

PRM

RNMI

MB

ECOLO

Kezhi Li China

Suguru Hayase Japan

J Gidáli Hungary

Benjamin Mitmaker Canada

Wen‐Lian Chen China

Paolo Marolla Italy

Matthew Pawlus United States

Christine Roos United States

Donald E. Mahan United States

Marc E. Wiles United States

Kezhi Li China

R Moroose

194 ×1.0

ONCOL

117 ×1.3

PRM

11 ×0.2

RNMI

228 ×3.2

MB

3 ×0.1

ECOLO

Citations per year, relative to R Moroose R Moroose (= 1×) peers Kezhi Li

Countries citing papers authored by R Moroose

Since Specialization

Citations

This map shows the geographic impact of R Moroose's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R Moroose with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R Moroose more than expected).

Fields of papers citing papers by R Moroose

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R Moroose. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R Moroose. The network helps show where R Moroose may publish in the future.

Co-authorship network of co-authors of R Moroose

This figure shows the co-authorship network connecting the top 25 collaborators of R Moroose. A scholar is included among the top collaborators of R Moroose based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R Moroose. R Moroose is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

1.

Stroyakovskiy, Daniil, DA Yardley, Chiun‐Sheng Huang, et al.. (2025). LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes. Annals of Oncology. 36. S1559–S1559.

2.

Fasching, Peter A., Daniil Stroyakovskiy, Denise A. Yardley, et al.. (2024). LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trial. Annals of Oncology. 35. S1207–S1207. 17 indexed citations

3.

Bardia, Aditya, Gabriel N. Hortobágyi, Oleg Lipatov, et al.. (2023). LBA23 Invasive disease–free survival (iDFS) across key subgroups from the phase III NATALEE study of ribociclib (RIB) + a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2- early breast cancer (EBC). Annals of Oncology. 34. S1261–S1262.

4.

Kalinsky, Kevin, Jennifer R. Diamond, Linda T. Vahdat, et al.. (2020). Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Annals of Oncology. 31(12). 1709–1718. 111 indexed citations

5.

Kalinsky, Kevin, SJ Isakoff, SM Tolaney, et al.. (2019). Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC). Cancer Research. 79(4_Supplement). P2–11. 3 indexed citations

6.

Hoffman, Justin, et al.. (2019). Abstract P3-14-07: Evaluation of the effects of talazoparib on QT interval prolongation. Cancer Research. 79(4_Supplement). P3–14.

7.

Bardia, Aditya, Linda T. Vahdat, Jennifer R. Diamond, et al.. (2018). Abstract GS1-07: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results. Cancer Research. 78(4_Supplement). GS1–7. 12 indexed citations

8.

Saura, Cristina, Binghe Xu, Wael A. Harb, et al.. (2011). P1-12-09: Safety and Efficacy of Neratinib in Combination with Capecitabine in Patients with ErbB2-Positive Breast Cancer.. Cancer Research. 71(24_Supplement). P1–12. 9 indexed citations

9.

Hurvitz, Sara A., Mark D. Pegram, David W. Chan, et al.. (2009). Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.. Cancer Research. 69(24_Supplement). 6094–6094. 37 indexed citations

10.

Saura, Cristina, Miguel Martín, R Moroose, et al.. (2009). Safety of Neratinib (HKI-272) in Combination with Capecitabine in Patients with Solid Tumors: A Phase 1/2 Study.. Cancer Research. 69(24_Supplement). 5108–5108. 14 indexed citations

11.

Hurvitz, Sara A., Heather Allen, R Moroose, et al.. (2008). Final results of a phase II study of bevacizumab plus docetaxel for the first-line treatment of metastatic breast cancer (TORI-B01). European Journal of Cancer Supplements. 6(7). 217–217. 1 indexed citations

12.

Perry, Antoinette S., Barbara Loftus, R Moroose, et al.. (2007). In silico mining identifies IGFBP3 as a novel target of methylation in prostate cancer. British Journal of Cancer. 96(10). 1587–1594. 37 indexed citations

13.

Beutler, Ernest, et al.. (1990). Gamma-glutamylcysteine synthetase deficiency and hemolytic anemia. Blood. 75(1). 271–273. 29 indexed citations

14.

Beutler, Ernest, et al.. (1990). Gamma-glutamylcysteine synthetase deficiency and hemolytic anemia. Blood. 75(1). 271–273. 2 indexed citations

15.

Weitzel, Jeffrey N., et al.. (1990). Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood. 76(12). 2555–2559. 5 indexed citations

16.

Weitzel, Jeffrey N., et al.. (1990). Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood. 76(12). 2555–2559. 64 indexed citations

17.

Moroose, R & Leon W. Hoyer. (1986). Von Willebrand Factor and Platelet Function. Annual Review of Medicine. 37(1). 157–163. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact